Objective The molecular regulatory mechanism of Zhanjin Huoxue Powder in treatment of soft tissue injury was initially explored by network pharmacology combined with molecular dock technology,which provided data support for the clinical use of Zhanjin Huoxue Powder. Methods TCMSP,ETCM and BATMAN-TCM databases were used to collect the components and targets of Zhanjin Huoxue Powder,while GeneCards and OMIM databases were used to obtain the targets of soft tissue injury. The main components and targets of Zhanjin Huoxue Powder in treatment of soft tissue injury were obtained by intersection of components and disease targets. The active components and intersection target network of Zhanjin Huoxue Powder for the treatment of soft tissue injury were constructed by Cytoscape software. The PPI network map of intersecting targets was constructed in STRING database,which was used for gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis by Weisheng and Ouyi Cloud platforms. Molecular docking technology was used to verify the combination strength of key components and targets of Zhanjin Huoxue Powder in treatment of soft tissue injury. Results In this study,40 active components of Zhanjin Huoxue Powder (ginsenoside Rh2,dracorhodin,daidzein,quercetin,kaempferol,phellamurin and coniferyl ferulate) were screened for 48 targets (immunoinflammatory cytokines IL-3,IL-4,IL-6,TLR4,TNF,and PTGS2;angiogenesis factors VEGFA,NOS3,and HMOX1;apoptosis factors CASP3,CASP8;hormone regulatory factors ESR1) and HIF-1,PI3K/Akt,IL-17,TNF,and 15 thyroid hormone signaling pathways involved in soft tissue injury. Molecular docking proved that the active components of Zhanjin Huoxue Powder had strong binding force with the corresponding soft tissue injury targets. Conclusion Zhanjin Huoxue Powder can treat soft tissue injury by targeting key targets IL-6,TLR4,TNF,CASP3,VEGFA,and ESR1 through ginsenoside Rh2,dracorhodin,daidzein,quercetin,kaempferol,phellamurin,and coniferyl ferulate.
NETL
NSTL
万方数据
